Literature DB >> 28449305

C-reactive protein variability is associated with vascular access outcome in hemodialysis patients.

Wei-Hung Kuo1, Yueh-Ting Lee1, Hwee-Yeong Ng1, Chun-Yeh Wang1, Chien-Hsing Wu1, Chien-Te Lee1.   

Abstract

BACKGROUND: Hemodialysis (HD) vascular access failure is one of the most important causes of morbidity and contributes to the cost of dialysis care. There is paucity of data evaluating long-term monitoring of C-reactive protein (CRP) on outcome of HD vascular access.
METHODS: We conducted a retrospective study to investigate whether variability of serum CRP level was associated with vascular access failure rate over a 7-year period. A total of 318 HD patients were included. Their demographic data, co-morbidities and biochemical data were reviewed and collected. Serum high-sensitivity CRP (hs-CRP) level was measured every 6 months. Patients were divided into three groups according to their serial hs-CRP levels. Patients with their hs-CRP below 2 mg/L were defined as low group (n=65, 20.4%) and those with higher than 4 mg/L were defined as high (n=39, 12.3%). The rest were classified as fluctuated hs-CRP group (n=214, 67.3%). Treatment of vascular access failure includes angioplasty and access re-creation.
RESULTS: Their body mass index, indicators of dialysis adequacy and serum albumin and hs-CRP levels differed significantly among three groups. The annual vascular access failure rate was significantly higher in fluctuated hs-CRP group than in high hs-CRP group (0.41 vs 0.36, P=.037). Serum albumin was a significant associate of vascular access failure. Kaplan-Meier survival analysis indicated patients with high or fluctuated hs-CRP had shorter free interval of vascular access failure than low hs-CRP group.
CONCLUSIONS: HD patients with fluctuated hs-CRP levels were associated with increased vascular access failure.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  C-reactive protein; hemodialysis; vascular access

Mesh:

Substances:

Year:  2017        PMID: 28449305      PMCID: PMC6817272          DOI: 10.1002/jcla.22213

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  31 in total

Review 1.  Cytokine dysregulation in chronic kidney disease: how can we treat it?

Authors:  Juan Jesus Carrero; Mahmut Ilker Yilmaz; Bengt Lindholm; Peter Stenvinkel
Journal:  Blood Purif       Date:  2008-04-18       Impact factor: 2.614

2.  Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment.

Authors:  T Nguyen-Khoa; Z A Massy; J P De Bandt ; M Kebede; L Salama; G Lambrey; V Witko-Sarsat; T B Drüeke; B Lacour; M Thévenin
Journal:  Nephrol Dial Transplant       Date:  2001-02       Impact factor: 5.992

3.  Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis.

Authors:  Damir Puskar; Josip Pasini; Ivan Savić; Goran Bedalov; Zdenko Sonicki
Journal:  Croat Med J       Date:  2002-06       Impact factor: 1.351

4.  Clinical efficacy of an automated high-sensitivity C-reactive protein assay.

Authors:  N Rifai; R P Tracy; P M Ridker
Journal:  Clin Chem       Date:  1999-12       Impact factor: 8.327

5.  Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarly associated with survival in haemodialysis patients.

Authors:  Christiaan L Meuwese; Sunna Snaedal; Nynke Halbesma; Peter Stenvinkel; Friedo W Dekker; Abdul R Qureshi; Peter Barany; Olof Heimburger; Bengt Lindholm; Raymond T Krediet; Els W Boeschoten; Juan J Carrero
Journal:  Nephrol Dial Transplant       Date:  2010-09-15       Impact factor: 5.992

6.  The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group.

Authors:  G A Kaysen; J A Dubin; H G Müller; L M Rosales; N W Levin
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

7.  Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity.

Authors:  Chi-Jen Chang; Yu-Shien Ko; Po-Jen Ko; Lung-An Hsu; Chin-Fen Chen; Chih-Wei Yang; Tsu-Shiu Hsu; Jong-Hwei S Pang
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

8.  Economic analysis of angiography and preemptive angioplasty to prevent hemodialysis-access thrombosis.

Authors:  John A Bittl; David J Cohen; Melvin M Seek; Robert L Feldman
Journal:  Catheter Cardiovasc Interv       Date:  2010-01-01       Impact factor: 2.692

9.  Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.

Authors:  Sunna Snaedal; Olof Heimbürger; Abdul Rashid Qureshi; Anders Danielsson; Björn Wikström; Bengt Fellström; Ingela Fehrman-Ekholm; Juan Jesús Carrero; Anders Alvestrand; Peter Stenvinkel; Peter Bárány
Journal:  Am J Kidney Dis       Date:  2009-04-25       Impact factor: 8.860

10.  Dysfunctional autogenous hemodialysis fistulas: outcomes after angioplasty--are there clinical predictors of patency?

Authors:  Dheeraj K Rajan; Sarah Bunston; Sanjay Misra; Ruxandra Pinto; Charmaine E Lok
Journal:  Radiology       Date:  2004-08       Impact factor: 11.105

View more
  3 in total

1.  C-reactive protein variability is associated with vascular access outcome in hemodialysis patients.

Authors:  Wei-Hung Kuo; Yueh-Ting Lee; Hwee-Yeong Ng; Chun-Yeh Wang; Chien-Hsing Wu; Chien-Te Lee
Journal:  J Clin Lab Anal       Date:  2017-04-27       Impact factor: 2.352

2.  The Influence of Sevelamer Hydrochloride and Calcium Carbonate on Markers of Inflammation and Oxidative Stress in Hemodialysis at Six Months of Follow-Up.

Authors:  Elodia Nataly Díaz-De la Cruz; José Ignacio Cerrillos-Gutiérrez; Andrés García-Sánchez; Carlos Gerardo Prado-Nevárez; Jorge Andrade-Sierra; Basilio Jalomo-Martínez; Adriana Banda-López; Enrique Rojas-Campos; Alejandra Guillermina Miranda-Díaz
Journal:  Front Med (Lausanne)       Date:  2021-11-25

3.  ESR, CRP, and failure of Arterio-Venous Fistula (AVF).

Authors:  Morteza Khavanin Zadeh; Zahra Omrani; Roozbeh Cheraghali; Mehdi Hashemaghaee
Journal:  Med J Islam Repub Iran       Date:  2021-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.